NCT06914609Phase 3Recruiting

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

Study sponsor: Ionis Pharmaceuticals, Inc. · IONS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-08Estimated

Enrollment · participants158Estimated

Source updated2026-08-28Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-12-22 · 2 fields changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) in Cohort 1

+ Updated value

measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) Without Caregiver Input in Cohort 1

The saved outcome text may be shortened. Check the source for full wording.

Enrollment · participant count

Recorded edit

− Previous value

count: 210; type: ESTIMATED

+ Updated value

count: 158; type: ESTIMATED

Check registry source

Study details

Conditions studied

Angelman Syndrome

Treatments or interventions studied

obudanersenDrugAlso known as ION582
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) Without Caregiver Input in Cohort 1; description: The Bayley-4 is a performance-based assessment of developmental functioning across communication, cognition, and motor skills. The expressive communication subdomain of communication measures preverbal and verbal communication. The total raw score reflects the sum of all the item scores within the expressive communication subdomain, with higher scores reflecting greater expressive communication ability.; timeFrame: Baseline and Week 52

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history